Filing summary
Issuer and period: The supplied filing is Trovagene, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2015—not a Cardiff Oncology filing. Trovagene described itself as a molecular diagnostics company developing urine-based cell-free DNA tests, with a primary focus on cancer monitoring.
Financial results and position
| Metric | Q1 2015 | Q1 2014 / comparison |
|---|---|---|
| Revenue | $126,970 | $110,953; up $16,017 |
| Cost of revenue | $176,425 | None reported |
| Operating expenses | $4,974,722 | $3,370,591 |
| Operating loss | $4,847,752 | $3,259,638 |
| Net loss attributable to common stockholders | $7,180,441; $0.33 per share | $3,199,006; $0.17 per share |
| Cash used in operations | $4,732,882 | $2,798,671 |
- Revenue comprised $124,804 of royalties and $2,166 of diagnostic services. Diagnostic service revenue was recognized on cash receipt; reported cost of revenue exceeded total revenue, implying negative gross margin for the quarter.
- Research and development rose to $2.20 million from $1.44 million, primarily reflecting expanded clinical collaborations, sample processing, and increased staffing. Selling and marketing increased to $795,000 from $570,000; general and administrative increased to $1.81 million from $1.36 million.
- Cash and cash equivalents were $44.0 million at March 31, 2015, versus $27.3 million at year-end 2014. Working capital was $39.2 million, versus $23.2 million at year-end.
- Total debt was approximately $15.1 million, including $3.06 million current and $12.01 million long-term. The term loan bears 7.07% interest; scheduled principal payments begin after interest-only payments through July 2015. The company reported compliance with loan covenants.
- Net cash from financing was $21.68 million, mainly from a February public offering. The company reported issuing 5.11 million shares in that offering and receiving approximately $21.3 million in net proceeds. Shares outstanding increased to 24.31 million at quarter-end from 18.90 million at year-end.
Changes, outlook, and risks
- Common-stockholder net loss more than doubled year over year. In addition to higher operating costs and interest expense, a $1.95 million non-cash loss from revaluing warrant derivative liabilities contributed to the increase. The derivative liability rose to $4.95 million from $3.01 million, primarily reflecting the higher share price.
- Management said operating cash outflows were expected to continue for several years and stated that additional capital would be required within the next 12 months. It cautioned that financing might not be available on acceptable terms; equity financing could dilute shareholders, while inability to raise funds could delay, reduce, or end development or commercialization plans.
- No quantified revenue, earnings, or cash-flow guidance was provided. Management expected R&D and selling, marketing, and general and administrative costs to increase as collaborations and commercial operations expanded. Royalty and diagnostic revenue timing was described as uncertain.
- Development and commercialization remained early-stage. Management cited clinical testing, regulatory review, product performance, financing needs, and competition from better-resourced organizations as risks. It reported no material changes to the risk factors in its 2014 Form 10-K, no material pending legal proceedings, and no off-balance-sheet arrangements.
- Management highlighted clinical study presentations involving colorectal, pancreatic, lung, and HPV testing; the results and performance statements are company-reported and should not be treated as independent validation.
Key facts for investors to verify
- Confirm issuer identity: this source is Trovagene, Inc., despite the Cardiff Oncology metadata.
- Review the stated need for additional capital within 12 months against quarter-end cash, expected spending, debt service, and subsequent financing disclosures.
- Check the terms, dilution, and remaining availability of the public offering and controlled equity offering programs.
- Assess the evidence, study design, and regulatory status supporting the company’s diagnostic performance and commercialization plans.
- Track diagnostic test volume, cash collections, and whether service revenue can exceed the associated testing costs as operations scale.